VistaGen Therapeutics (VTGN) announced its Q4 2025 financial results after market close.
The company reported revenue of -$0.02 million, falling short of the estimated $0.32 million and down from $0.2 million a year ago.
Earnings showed a loss of $0.44 per share, better than the estimated loss of $0.5 and an improvement from a $0.25 loss the prior year.